Breaking Canadian GLP-1 news
GLP-1 News — Page 9
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Find my best option
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Aspen Pharma Targets Q3 2026 Generic Semaglutide Launch
Aspen Pharmacare sets specific third quarter 2026 target for generic semaglutide launch in Canada, joining nine companies seeking Health Canada approval.
Vimy Pharma to File Generic Semaglutide Application Soon
Edmonton-based Vimy Pharma expects to submit its Health Canada application for generic semaglutide within weeks, joining eight other companies in review.
Health Canada Adds Submission Class Data to Public Tracker
Health Canada's drug review tracker now shows submission 'class' details including Access Consortium reviews as of March 20, expanding transparency.
Eli Lilly Cuts U.S. Zepbound Price Following Canada Reductions
Eli Lilly reduces U.S. Zepbound pricing for single-dose vials after cutting Canadian prices 20% in December, expanding affordability strategy globally.
Pfizer Develops Long-Acting GLP-1 Drug to Challenge Market
Pfizer is developing a long-acting GLP-1 drug that could compete directly with Eli Lilly's Mounjaro and Zepbound when it reaches the Canadian market.
Health Canada Adds New Tracking Features for Generic Reviews
Health Canada's March 20 update to drug review tracking now shows submission class and Access Consortium status for all completed reviews including generics.
3 Million Canadians Use GLP-1 Drugs, Survey Reveals High Demand
New survey data shows approximately 3 million Canadian adults currently take GLP-1 medications like Ozempic and Mounjaro, with many more seeking access.
India Launches Generic Semaglutide at $14 Monthly This Weekend
India becomes first major market to launch generic semaglutide at $14 monthly, with 50 brands expected as Canada awaits Health Canada approvals for nine applications.
Generic Semaglutide Could Cost Just $15 Monthly Worldwide
New reports indicate generic semaglutide could be priced as low as $15 monthly or $3 per dose globally, significantly undercutting current brand prices.
Novo Nordisk Considers Renamed Ozempic to Fight Generics
Novo Nordisk explores launching a lower-priced, renamed version of Ozempic in Canada as nine generic semaglutide applications undergo Health Canada review.
Health Canada Approves Heart Protection for Rybelsus Pill
Health Canada approves new cardiovascular indication for Rybelsus semaglutide pill, making it first oral GLP-1 with heart protection approval in Canada.
PharmaTher Joins Generic Semaglutide Race in Canada
PharmaTher launches strategic initiative to pursue Health Canada approval for generic semaglutide as regulatory exclusivity ended in January 2026.
Provinces Await Health Canada Approval Before Generic Coverage
Most provinces tell insurers they're waiting on Health Canada approvals before deciding coverage policies for generic semaglutide medications.
Health Canada's 180-Day Generic Review Beats Global Timelines
Health Canada's 180-day generic drug review timeline is shorter than similar regulatory agencies worldwide, potentially accelerating generic GLP-1 approvals.
Public Plans Should Cover Generic GLP-1s, Expert Says
Healthcare expert recommends public insurance plans cover generic semaglutide when available, citing accessibility benefits. Latest from GLP1Prices.ca
Novo Nordisk Cuts Wegovy Cash Price to $349 Monthly in Canada
Novo Nordisk announces new $349 monthly cash price for Wegovy in Canada, representing significant reduction from previous pricing - GLP1Prices.ca
Health Canada Issues Counterfeit GLP-1 Drug Warning
Health Canada warns Canadians about fake semaglutide and tirzepatide products as demand grows. Get the latest on GLP1Prices.ca
Health Canada Sets 180-Day Review Timeline for Generic GLP-1s
Health Canada confirms 180-day target timeline for reviewing nine generic semaglutide applications currently under regulatory assessment. GLP1Prices.ca
Retatrutide Triple Agonist Drug Enters Phase 3 Trials in Canada
Health Canada has not yet approved retatrutide, but the experimental triple agonist GLP-1 medication is advancing through clinical trials - GLP1Prices.ca
Health Canada Issues Notice of Compliance for New Wegovy Indication
Health Canada granted Notice of Compliance under NOC/c policy for new Wegovy indication in January 2026. Latest regulatory updates at GLP1Prices.ca
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada